Soleno Therapeutics’ stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.
Popular News
-
HMRC Connect system now holds 55bn data items in bid to tackle tax evasion
-
How to Contact Hilton Customer Service
-
How cyberattacks on grocery stores could threaten food security
-
Electric vehicles are ‘£350 a year’ cheaper to run than petrol cars – but only if you can charge at home
-
Here’s how long the three oil shock-induced bear markets lasted
Latest News
The Arlo Essential Pan Tilt Security Camera 2K Is 70% Off Right Now
We may earn a commission from links on this page. Deal pricing and availability subject to change after time of...
Standard Chartered Bank Predicts $500K Bitcoin as Price Climbs
Standard Chartered has put a $500,000 Bitcoin price target on the table for 2030, and the market nudged higher in...
Jamie Dimon isn’t too worried about private credit, but he sees another problem for markets
Jamie Dimon warns of a “skunk at the party” in 2026 in the form of rising inflation leading to a...
Think Your Crypto Is Liquid? Korea’s New Asset‑Matching Regime Says Think Again
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure South Korea’s Financial Services Commission (FSC) is...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.